Results 31 to 40 of about 5,663,878 (222)
Screening for primary aldosteronism on and off interfering medications
Endocrine, 2023 Objective To determine whether antihypertensives will affect diagnostic accuracy of the aldosterone-to-renin ratio (ARR) to an extent that is clinically relevant. Methods Confirmatory tests were used to confirm or exclude PA diagnosis.
Xiaoyu Li +16 more
semanticscholar +1 more source
Detecting primary aldosteronism in Australian primary care: a prospective study
Medical Journal of Australia, 2022 To assess the identification of primary aldosteronism (PA) in newly diagnosed, treatment‐naïve patients with hypertension by screening in primary care.
Renata Libianto +8 more
semanticscholar +1 more source
Primary Aldosteronism and Cardiovascular Events: It is time to take guideline recommendations seriously [PDF]
, 2018 It is nowadays widely accepted that primary aldosteronism is the most frequent cause of endocrine hypertension. Prevalence rates among patients with hypertension are 6% in the primary care setting and 11% in tertiary care referral centers (1).
Martin Reincke, Reincke, Martin
core +1 more source
Journal of Clinical Endocrinology and Metabolism, 2016 OBJECTIVE To develop clinical practice guidelines for the management of patients with primary aldosteronism. PARTICIPANTS The Task Force included a chair, selected by the Clinical Guidelines Subcommittee of the Endocrine Society, six additional experts,
J. Funder +7 more
semanticscholar +1 more source
Disordered CYP11B2 Expression in Primary Aldosteronism [PDF]
, 2017 Primary aldosteronism is the most common type of secondary hypertension affecting 6-10% of patients with primary hypertension. PA is mainly caused by unilateral hyperaldosteronism due to an aldosterone-producing adenoma, unilateral hyperplasia with or ...
Maniselvan Kuppusamy +8 more
core +1 more source
Hypertension, 2014 See related article, p 783–789 Primary aldosteronism (PA) is the most common form of secondary hypertension accounting for ≈10% of patients referred to hypertension clinics and as high as 20% of those with refractory hypertension.1 The most important causes of PA are idiopathic hyperaldosteronism (IHA), also called bilateral zona glomerulosa ...
openaire +5 more sources
Primary Aldosteronism and Resistant Hypertension: A Pathophysiological Insight
International Journal of Molecular Sciences, 2022 Primary aldosteronism (PA) is a pathological condition characterized by an excessive aldosterone secretion; once thought to be rare, PA is now recognized as the most common cause of secondary hypertension.
F. Bioletto +8 more
semanticscholar +1 more source
Cerebro-Cardiovascular Risk, Target Organ Damage, and Treatment Outcomes in Primary Aldosteronism
Frontiers in Cardiovascular Medicine, 2022 Primary aldosteronism (PA) is the most common type of endocrine hypertension, and numerous experimental and clinical evidence have verified that prolonged exposure to excess aldosterone is responsible for an increased risk of cerebro-cardiovascular ...
Xiao Lin +7 more
semanticscholar +1 more source
Primary Aldosteronism or Not Primary Aldosteronism [PDF]
Hypertension, 2017 See related article, pp 950–956 Primary aldosteronism (PA) within hypertensive populations is no longer regarded as being a rare phenomenon. Although some debate around its overall frequency remains, one of the most robust studies in recent years describes a prevalence of ≈10% in unselected hypertensives1; this may rise to ≤20% in subjects with ...
openaire +2 more sources
THERAPY OF ENDOCRINE DISEASE: Medical treatment of primary aldosteronism [PDF]
, 2019 In patients with primary aldosteronism specific treatment provides prognostic benefit over optimal antihypertensive therapy and is therefore crucial to reduce mortality and morbidity in this subgroup of patients with hypertension.
Lechner, Benjamin +8 more
core +1 more source